Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.

Autor: Ajjawi I; Yale School of Medicine, New Haven, Connecticut., Loeb S; Department of Urology, New York University Langone Health, New York.; Manhattan Veterans Affairs Medical Center, New York, New York., Cooperberg MR; Department of Urology, University of California, San Francisco.; Department of Epidemiology and Biostatistics, University of California, San Francisco., Catalona WJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Gross CP; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.; Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut., Ma X; Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Leapman MS; Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut.; Department of Urology, Yale School of Medicine, New Haven, Connecticut.

Publikováno v: JAMA [JAMA] 2024 Nov 20. Date of Electronic Publication: 2024 Nov 20.

Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy.

Autor: Lokeshwar SD; Yale University, School of Medicine, Department of Urology, New Haven, CT., Choksi AU; Yale University, School of Medicine, Department of Urology, New Haven, CT., Smani S; Yale University, School of Medicine, Department of Urology, New Haven, CT., Kong V; Yale University, School of Medicine, Department of Urology, New Haven, CT., Sundaresan V; Yale University, School of Medicine, Department of Urology, New Haven, CT., Sutherland R; Yale University, School of Medicine, Department of Urology, New Haven, CT., Brito J; Yale University, School of Medicine, Department of Urology, New Haven, CT., Renzulli JF; Yale University, School of Medicine, Department of Urology, New Haven, CT., Sprenkle PC; Yale University, School of Medicine, Department of Urology, New Haven, CT., Leapman MS; Yale University, School of Medicine, Department of Urology, New Haven, CT. Electronic address: michael.leapman@yale.edu.

Publikováno v: Urologic oncology [Urol Oncol] 2024 Nov 08. Date of Electronic Publication: 2024 Nov 08.

Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.

Autor: Sundaresan VM; Department of Urology, Yale School of Medicine, New Haven, Connecticut., Wang R; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Long JB; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Sprenkle PC; Department of Urology, Yale School of Medicine, New Haven, Connecticut., Seibert TM; Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.; Department of Radiology, University of California, San Diego, La Jolla, California.; Department of Bioengineering, University of California, San Diego, La Jolla, California., Loeb S; Departments of Urology and Population Health, New York University Langone Health, New York, New York.; Manhattan Veterans Affairs Medical Center, New York, New York., Cooperberg MR; Department of Urology, University of California, San Francisco, San Francisco, California.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California., Catalona WJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Ma X; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Gross CP; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Leapman MS; Department of Urology, Yale School of Medicine, New Haven, Connecticut.; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.

Publikováno v: Urology practice [Urol Pract] 2024 Nov; Vol. 11 (6), pp. 965-973. Date of Electronic Publication: 2024 Jul 16.

Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients with Low-Risk Prostate Cancer in the Community Practice.

Autor: Gaylis FD; Division of Urology, Genesis Healthcare Partners, San Diego, California., Leapman MS; Department of Urology, Yale School of Medicine, New Haven, Connecticut., Ellis SD; Department of Population Health, Kansas University Medical Center, The University of Kansas., Hu S; Preveta Inc, California., Cooperberg MR; Department of Urology, University of California San Francisco, San Francisco, California.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Loeb S; Departments of Urology and Population Health, New York University Langone Health, New York, New York.; Manhattan Veterans Affairs Medical Center, New York, New York., Chen RC; Department of Radiation Oncology, Kansas University Medical Center, The University of Kansas., Cohen ES; Division of Urology, Genesis Healthcare Partners, San Diego, California., Dato PE; Division of Urology, Genesis Healthcare Partners, San Diego, California., Aynehchi S; Division of Urology, Genesis Healthcare Partners, San Diego, California., David R; Division of Urology, Genesis Healthcare Partners, San Diego, California., Topp R; College of Nursing, University of Kentucky, Lexington, Kentucky., Santomauro B; Division of Urology, Genesis Healthcare Partners, San Diego, California., Ginsburg K; Department of Urology, Wayne State University School of Medicine, Detroit. Michigan., Catalona WJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Publikováno v: Urology practice [Urol Pract] 2024 Oct 25, pp. 101097UPJ0000000000000745. Date of Electronic Publication: 2024 Oct 25.

Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review.

Autor: Fazekas T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary., Pallauf M; Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria., Kufel J; Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland., Miszczyk M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum, Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland., Tsuboi I; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan., Matsukawa A; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan., Laukhtina E; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia., Kardoust Parizi M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran., Mancon S; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy., Cadenar A; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Unit of Oncologic Minimally Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy., Schulz R; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University Center Hamburg-Eppendorf, Hamburg, Germany., Yanagisawa T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan., Baboudjian M; Department of Urology, North Academic Hospital, AP-HM, Marseille, France., Szarvas T; Department of Urology, Semmelweis University, Budapest, Hungary; Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany., Gandaglia G; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy., Tilki D; Department of Urology, Medical University Center Hamburg-Eppendorf, Hamburg, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey., Nyirády P; Department of Urology, Semmelweis University, Budapest, Hungary; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary., Rajwa P; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Surgery and Interventional Science, University College London, London, UK; Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland., Leapman MS; Department of Urology, Yale School of Medicine, New Haven, CT, USA., Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: shahrokh.shariat@meduniwien.ac.at.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Oct 15. Date of Electronic Publication: 2024 Oct 15.